Compare MD & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | NTLA |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 1996 | 2016 |
| Metric | MD | NTLA |
|---|---|---|
| Price | $23.42 | $15.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 23 |
| Target Price | ★ $20.50 | $20.02 |
| AVG Volume (30 Days) | 580.5K | ★ 6.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.03 | 27.43 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,913,849,000.00 | $67,671,000.00 |
| Revenue This Year | $3.72 | N/A |
| Revenue Next Year | $2.62 | $62.75 |
| P/E Ratio | $65.25 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $11.84 | $7.95 |
| 52 Week High | $24.99 | $28.24 |
| Indicator | MD | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 62.15 |
| Support Level | $21.05 | $11.73 |
| Resistance Level | $24.02 | $17.03 |
| Average True Range (ATR) | 0.67 | 1.31 |
| MACD | 0.13 | 0.28 |
| Stochastic Oscillator | 68.82 | 78.46 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.